SecBot SecBot
8-K ·Filed Apr 23, 2026

BZYR

BURZYNSKI RESEARCH INSTITUTE INC
NEUTRAL
Impact 3/10
Horizonweeks Processed6mo ago SEC0001104659-26-047711
8-K context-dependent: Items 5.02
Actionable Insight • Neutral

Monitor upcoming financial filings for any changes in financial reporting quality or internal controls given the consolidation of top executive and financial roles within a single individual who is also the controlling stockholder.

DirectionNeutral
Confidencehigh
Horizonweeks
Final — all horizons settled through T+60d
BZYR ▼ -81.25% at T+60d
NEUTRAL call -81.25% · α vs SPY -86.33% · entry $0.0320 → $0.006000
Entry = T+0 close
Apr 23, 2026
via day close
T+1d
0.00%
call 0.00% · α -0.16%
$0.0320
settled 6mo ago
T+5d
-53.13%
call -53.13% · α -54.03%
$0.0150
settled 6mo ago
T+20d
-65.63%
call -65.63% · α -69.65%
$0.0110
settled 5mo ago
T+60d
-81.25%
call -81.25% · α -86.33%
$0.006000
settled 3mo ago

Price Chart

Loading chart...

Executive Summary

Patryk P. Goscianski resigned as CFO and Secretary of Burzynski Research Institute, Inc. effective April 17, 2026, due to personal reasons. He was succeeded by Dr. Stanislaw R. Burzynski, the company's controlling stockholder, President, and Chairman, who will now serve as both principal executive and financial officer without additional compensation.

Key Facts

  • Patryk P. Goscianski resigned as CFO and Secretary effective April 17, 2026, citing personal reasons.
  • Dr. Stanislaw R. Burzynski, the company's controlling stockholder and current President and Chairman, was appointed as the new CFO and Secretary.
  • Dr. Burzynski will serve as both principal executive officer and principal financial officer and will not receive additional compensation.
  • The resignation was not due to any disagreement with the company on operations, policies, or practices.

Financial Impact

No immediate financial impact disclosed; no change in compensation structure.

compensationexecutive leadership

Risk Factors

  • Concentration of power in a single individual (CEO, CFO, Chairman, controlling shareholder) may increase governance risks.
  • Potential for reduced financial oversight and internal control given the dual role of principal executive and financial officer.

Market Snapshot

Exchange
OTC
Sector
In Vitro & In Vivo Diagnostic Substances

Investment Themes

Documents Analyzed

This report is based on 5 SEC documents filed with EDGAR.

DocumentAccession Number
8-K Filing (Primary)0001104659-26-047711
Document: tm2612461d1_ex17-1.htm0001104659-26-047711
Document: 0001104659-26-047711-index-headers.html0001104659-26-047711
Document: 0001104659-26-047711-index.html0001104659-26-047711
Document: 0001104659-26-047711.txt0001104659-26-047711

US Market Status

Market Closed — Opens Thu (12h 4m)

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published Apr 23, 2026